Patients received either BOW015 or rIFX as 3 mg/kg intravenously (IV) every eight weeks—at Weeks 0, 2, 6 and 14. Patients then received open-label BOW015 through Week 54. At Week 16, clinically significant improvements from baseline were noted for both scores in both treatment groups. Significant reductions in DAS and disability were maintained throughout the study’s open-label phase to week 54.
Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
References
- Vencovský J, Sylwestrzak A, Leszczyński P, et al. A phase 3 randomized, double-blind clinical study comparing sb4, an etanercept biosimilar, with etanercept reference product (Enbrel®) in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy (24-week results). Ann Rheum Dis. June 2015;74(Suppl2):467. Abstract FRI0128. doi: 10.1136/annrheumdis-2015-eular.1220
- Santos-Moreno P, Saavedra-Martinez G, Villarreal L, et al. Etanar—A etanercept biosimilar is as effective as adalimumab and infliximab in a cohort of real-life of patients with rheumatoid arthritis. Ann Rheum Dis. June 2015;74(Suppl2):789. Abstract SAT0360. doi: 10.1136/annrheumdis-2015-eular.2508
- Kay J, Chopra A, Lassen C, Shneyer L, Wyand M. BOW015, a biosimilar infliximab: Disease activity and disability outcomes from a phase 3 active comparator study in patients with active rheumatoid arthritis on stable methotrexate doses. Ann Rheum Dis. June 2015;74(Suppl2):462. Abstract FRI0117. doi: 10.1136/annrheumdis-2015-eular.4973.